Business Context and Reporting Period
This Form 8-K Current Report was filed by OncoCyte Corporation on August 29, 2016. The filing discloses the closing of a private placement offering of equity securities. Note: While the request metadata references "Insight Molecular Diagnostics Inc.", the filing text explicitly identifies the registrant as OncoCyte Corporation.
Key Financial Metrics
- Gross Proceeds: Approximately $10.5 million raised from the offering.
- Units Sold: 3,246,153 units.
- Price Per Unit: $3.25.
- Placement Agent Commission: $511,000 paid in cash to Cowen and Company, LLC.
- Warrant Exercise Price: $3.25 per share.
Material Changes and Transaction Details
On August 29, 2016, OncoCyte sold units consisting of one share of common stock and one warrant to purchase one share of common stock. The sale was made to institutional and accredited individual investors, including existing shareholder George Karfunkel (beneficial owner of more than 5% of outstanding common stock). The transaction was conducted under exemptions provided by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
Key terms of the warrants include:
- Exercisable on the earlier of November 28, 2016, or the date of shareholder approval.
- Five-year exercise period from the date they become exercisable.
- Net settlement required for exercises prior to shareholder approval.
Guidance, Outlook, and Obligations
The filing does not provide specific financial guidance or operational outlook beyond the transaction details. However, OncoCyte has agreed to the following obligations:
- File a resale registration statement with the SEC by October 28, 2016.
- Cause the resale registration statement to become effective by November 28, 2016.
- Use reasonable best efforts to obtain shareholder approval for the issuance of shares upon warrant exercise.
Forward-looking statements in the filing are subject to risks detailed in the company's Form 10-K and 10-Q filings.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the $511,000 placement agent commission and other transaction costs.
- Confirm the status of the shareholder approval required for full warrant exercise.
- Review the resale registration statement (to be filed by October 28, 2016) for any lock-up provisions or additional terms.
- Assess the impact of the 3,246,153 new shares on existing shareholder dilution.
- Check subsequent filings to confirm the effectiveness date of the resale registration statement.